The Department monitors and manages medicine supply at a national level so that stocks remain available to meet regional and local demand. Information is not collected on a local level.<\/p>
The Department has been working hard with industry and NHS England to help resolve supply issues with some attention deficit hyperactivity disorder (ADHD) medicines, which are affecting the United Kingdom and other countries around the world. As a result of intensive work, some issues have been resolved and all strengths of lisdexamfetamine, atomoxetine capsules, and guanfacine prolonged-release tablets are now available.<\/p>
We are continuing to work to resolve supply issues where they remain, for methylphenidate prolonged-release tablets. We are engaging with all suppliers of methylphenidate prolonged-release tablets to assess the challenges faced and their actions to address them. We are also directing suppliers to secure additional stocks, expedite deliveries where possible, and review plans to further build capacity to support continued growth in demand for the short and long-term. We anticipate intermittent regional supply disruptions to continue, and we expect supply to improve in the UK from October 2024.<\/p>
In parallel, the Department has worked with specialist clinicians, including those within the National Health Service, to develop management advice for NHS clinicians to consider prescribing available alternative brands of methylphenidate prolonged release tablets or available alternative ADHD medicines. We would expect ADHD service providers and specialists to follow our guidance, which includes offering rapid response to primary care teams seeking urgent advice or opinion for the management of patients, including those known to be at a higher risk of adverse impact because of these shortages.<\/p>
To aid ADHD service providers and prescribers further we have widely disseminated our communications, and continually update a list of currently available and unavailable ADHD products on the Specialist Pharmacy Service website, helping ensure that those involved in the prescribing and dispensing of ADHD medications can make informed decisions with patients.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4444", "label" : {"_value" : "Biography information for Karin Smyth"} } , "answeringMemberConstituency" : {"_value" : "Bristol South"} , "answeringMemberPrinted" : {"_value" : "Karin Smyth"} , "dateOfAnswer" : {"_value" : "2024-10-11", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "7532"} , {"_value" : "7533"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-10-11T08:39:25.353Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-10-07", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Attention Deficit Hyperactivity Disorder: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to help people who are unable to access the ADHD medication they need.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4673", "label" : {"_value" : "Biography information for Jo Platt"} } , "tablingMemberConstituency" : {"_value" : "Leigh and Atherton"} , "tablingMemberPrinted" : [{"_value" : "Jo Platt"} ], "uin" : "7531"} , {"_about" : "http://data.parliament.uk/resources/1732044", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1732044/answer", "answerText" : {"_value" : "
The Department monitors and manages medicine supply at a national level so that stocks remain available to meet regional and local demand. Information is not collected on a local level.<\/p>
The Department has been working hard with industry and NHS England to help resolve supply issues with some attention deficit hyperactivity disorder (ADHD) medicines, which are affecting the United Kingdom and other countries around the world. As a result of intensive work, some issues have been resolved and all strengths of lisdexamfetamine, atomoxetine capsules, and guanfacine prolonged-release tablets are now available.<\/p>
We are continuing to work to resolve supply issues where they remain, for methylphenidate prolonged-release tablets. We are engaging with all suppliers of methylphenidate prolonged-release tablets to assess the challenges faced and their actions to address them. We are also directing suppliers to secure additional stocks, expedite deliveries where possible, and review plans to further build capacity to support continued growth in demand for the short and long-term. We anticipate intermittent regional supply disruptions to continue, and we expect supply to improve in the UK from October 2024.<\/p>
In parallel, the Department has worked with specialist clinicians, including those within the National Health Service, to develop management advice for NHS clinicians to consider prescribing available alternative brands of methylphenidate prolonged release tablets or available alternative ADHD medicines. We would expect ADHD service providers and specialists to follow our guidance, which includes offering rapid response to primary care teams seeking urgent advice or opinion for the management of patients, including those known to be at a higher risk of adverse impact because of these shortages.<\/p>
To aid ADHD service providers and prescribers further we have widely disseminated our communications, and continually update a list of currently available and unavailable ADHD products on the Specialist Pharmacy Service website, helping ensure that those involved in the prescribing and dispensing of ADHD medications can make informed decisions with patients.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4444", "label" : {"_value" : "Biography information for Karin Smyth"} } , "answeringMemberConstituency" : {"_value" : "Bristol South"} , "answeringMemberPrinted" : {"_value" : "Karin Smyth"} , "dateOfAnswer" : {"_value" : "2024-10-11", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "7531"} , {"_value" : "7533"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-10-11T08:39:25.383Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-10-07", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Attention Deficit Hyperactivity Disorder: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what steps he is taking to coordinate a local plan with (a) NHS Trusts and (b) healthcare organisations to help tackle shortages of ADHD medication .", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4673", "label" : {"_value" : "Biography information for Jo Platt"} } , "tablingMemberConstituency" : {"_value" : "Leigh and Atherton"} , "tablingMemberPrinted" : [{"_value" : "Jo Platt"} ], "uin" : "7532"} , {"_about" : "http://data.parliament.uk/resources/1732045", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1732045/answer", "answerText" : {"_value" : "
The Department monitors and manages medicine supply at a national level so that stocks remain available to meet regional and local demand. Information is not collected on a local level.<\/p>
The Department has been working hard with industry and NHS England to help resolve supply issues with some attention deficit hyperactivity disorder (ADHD) medicines, which are affecting the United Kingdom and other countries around the world. As a result of intensive work, some issues have been resolved and all strengths of lisdexamfetamine, atomoxetine capsules, and guanfacine prolonged-release tablets are now available.<\/p>
We are continuing to work to resolve supply issues where they remain, for methylphenidate prolonged-release tablets. We are engaging with all suppliers of methylphenidate prolonged-release tablets to assess the challenges faced and their actions to address them. We are also directing suppliers to secure additional stocks, expedite deliveries where possible, and review plans to further build capacity to support continued growth in demand for the short and long-term. We anticipate intermittent regional supply disruptions to continue, and we expect supply to improve in the UK from October 2024.<\/p>
In parallel, the Department has worked with specialist clinicians, including those within the National Health Service, to develop management advice for NHS clinicians to consider prescribing available alternative brands of methylphenidate prolonged release tablets or available alternative ADHD medicines. We would expect ADHD service providers and specialists to follow our guidance, which includes offering rapid response to primary care teams seeking urgent advice or opinion for the management of patients, including those known to be at a higher risk of adverse impact because of these shortages.<\/p>
To aid ADHD service providers and prescribers further we have widely disseminated our communications, and continually update a list of currently available and unavailable ADHD products on the Specialist Pharmacy Service website, helping ensure that those involved in the prescribing and dispensing of ADHD medications can make informed decisions with patients.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4444", "label" : {"_value" : "Biography information for Karin Smyth"} } , "answeringMemberConstituency" : {"_value" : "Bristol South"} , "answeringMemberPrinted" : {"_value" : "Karin Smyth"} , "dateOfAnswer" : {"_value" : "2024-10-11", "_datatype" : "dateTime"} , "groupedQuestionUIN" : [{"_value" : "7531"} , {"_value" : "7532"} ], "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2024-10-11T08:39:25.413Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2024-10-07", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Attention Deficit Hyperactivity Disorder: Drugs"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what progress his Department is making with manufacturers on resolving issues of ADHD medicine supply.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4673", "label" : {"_value" : "Biography information for Jo Platt"} } , "tablingMemberConstituency" : {"_value" : "Leigh and Atherton"} , "tablingMemberPrinted" : [{"_value" : "Jo Platt"} ], "uin" : "7533"} , {"_about" : "http://data.parliament.uk/resources/1151449", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1151449/answer", "answerText" : {"_value" : "
The data is not available in the format requested.<\/p>"} , "answeringMember" : {"_about" : "http://data.parliament.uk/members/4380", "label" : {"_value" : "Biography information for Jo Churchill"} } , "answeringMemberConstituency" : {"_value" : "Bury St Edmunds"} , "answeringMemberPrinted" : {"_value" : "Jo Churchill"} , "dateOfAnswer" : {"_value" : "2019-10-30", "_datatype" : "dateTime"} , "isMinisterialCorrection" : {"_value" : "false", "_datatype" : "boolean"} , "questionFirstAnswered" : [{"_value" : "2019-10-30T17:46:56.137Z", "_datatype" : "dateTime"} ]} , "answeringDeptId" : {"_value" : "17"} , "answeringDeptShortName" : {"_value" : "Health and Social Care"} , "answeringDeptSortName" : {"_value" : "Health and Social Care"} , "date" : {"_value" : "2019-10-22", "_datatype" : "dateTime"} , "hansardHeading" : {"_value" : "Health Visitors"} , "houseId" : {"_value" : "1"} , "legislature" : [{"_about" : "http://data.parliament.uk/terms/25259", "prefLabel" : {"_value" : "House of Commons"} } ], "questionText" : "To ask the Secretary of State for Health and Social Care, what recent estimate he has made of the number of health visitors in England in each year since 2010.", "registeredInterest" : {"_value" : "false", "_datatype" : "boolean"} , "tablingMember" : {"_about" : "http://data.parliament.uk/members/4673", "label" : {"_value" : "Biography information for Jo Platt"} } , "tablingMemberConstituency" : {"_value" : "Leigh"} , "tablingMemberPrinted" : [{"_value" : "Jo Platt"} ], "uin" : "3796"} , {"_about" : "http://data.parliament.uk/resources/1151451", "AnsweringBody" : [{"_value" : "Department of Health and Social Care"} ], "answer" : {"_about" : "http://data.parliament.uk/resources/1151451/answer", "answerText" : {"_value" : "
Health visiting is an essential part of broader early years family support. The number of health visitors employed by National Health Service organisations reported through Electronic Staff Records shows reduction, but this is not a complete picture of the workforce as this goes not include social enterprises, private sector organisations or local authorities. It is the responsibility of local authorities to determine how the programme is provided to their communities based upon local needs.<\/p>
Data on mandated health visitor reviews shows national coverage remains above those achieved in 2015. However, there is variation at a local level. Data is available at the following link:<\/p>
https://www.gov.uk/government/statistics/health-visitor-service-delivery-metrics-2018-to-2019<\/a><\/p> Progress against health and wellbeing outcomes for the zero to five years population, and inequalities in these outcomes, is published in Early Years Profiles at the following link:<\/p>